Claims:

1. A topical composition for intranasal administration comprising alcaftadine or a pharmaceutically acceptable salt thereof and a corticosteroid or a pharmaceutically acceptable salt thereof.

2. The topical composition of claim 1, wherein the alcaftadine is in free form.

3. The topical composition of claim 1 or 2, wherein the corticosteroid is selected from alclometasone, beclometasone, betametasone, budesonide, ciclesonide, clobetasol, clobetasone, deflazacort, deprodone, dexamethasone, diflucortolone, fluocinolone, etiprednol, flunisolide, fluocinonide, fluocortolone, fluprednidene, flurometholone, fluticasone, halcinonide, hydrocortisone, loteprednol, methylprednisolone, mometasone, prednisolone, rimexolone, triamcinolone, esters thereof, and pharmaceutically acceptable salts thereof.

4. The topical composition of claim 1 or 2, wherein the corticosteroid is selected from beclomethasone, mometasone and esters thereof, fluticasone and esters thereof, budesonide, ciclesonide, and pharmaceutically acceptable salts thereof.

5. The topical composition of claim 1 or 2, wherein the corticosteroid is fluticasone furoate.

6. The topical composition of claim 1 or 2, wherein the corticosteroid is fluticasone propionate.

7. The topical composition of any of the preceding claims, further comprising a suspending agent.

8. The topical composition of any of the preceding claims, further comprising a preservative.

9. The topical composition of any of the preceding claims, further comprising at least 0.0125% w/w benzalkonium chloride, based upon the total weight of the composition.

10. The topical composition of any of the preceding claims, further comprising a buffering agent, a tonicity adjustment agent, a chelating agent, or any combination of any of the foregoing.

11. The topical composition of claim 10, wherein the buffering agent is monobasic sodium phosphate.

12. The topical composition of claim 10 or 11, wherein the tonicity adjustment agent is sodium chloride.

13. The topical composition of any one of claims 10-12, wherein the chelating agent is disodium edetate.

14. An aqueous nasal pharmaceutical composition comprising (i) 0.05 to 5% w/w alcaftadine or a pharmaceutically acceptable salt thereof, (ii) 0.01 to 5% w/w fluticasone furoate or fluticasone propionate, (iii) optionally 0.01 to 1.0% w/w suspending agent, (iv) 0.068 to 6.8% w/w sodium chloride, (v) 0.0019 to 0.19% w/w monobasic sodium phosphate, (v) 0.005 to 0.5% w/w disodium edetate, (vi) 0.0025 to 0.25% w/w benzalkonium chloride, (vii) 0.001 to 0.5% w/w polysorbate 80, and (viii) 0.5 to 15% w/w of a co-spray dried combination of microcrystalline cellulose and sodium carboxymethylcellulose, wherein the composition has a pH of 6.0 to 7.5.

15. An aqueous nasal pharmaceutical composition comprising (i) 0.125% w/w alcaftadine, (ii) 0.036% w/w fluticasone propionate or 0.02% w/w fluticasone furoate, (iii) 0.068 to 6.8% w/w sodium chloride, (iv) 0.0019 to 0.19% w/w monobasic sodium phosphate, (v) 0.005 to 0.5% w/w disodium edetate, (vi) 0.0025 to 0.25% w/w benzalkonium chloride, (vii) 0.001 to 0.5% w/w w/w polysorbate 80, and (viii) 0.5 to 15% w/w of a co-spray dried combination of microcrystalline cellulose and sodium carboxymethylcellulose, wherein the composition has a pH of 6.0 to 7.5.

16. An aqueous nasal pharmaceutical composition comprising (i) 0.125% w/w alcaftadine, (ii) 0.036% w/w fluticasone propionate or 0.02% w/w fluticasone furoate, (iii) 0.68 % w/w sodium chloride, (iv) 0.019 % w/w monobasic sodium phosphate, (v) 0.05% w/w disodium edetate, (vi) 0.0125% w/w benzalkonium chloride, (vii) 2.1% glycerine, (viii) 0.003% w/w

polysorbate 80, and (ix) 3.64% w/w of a co-spray dried combination of microcrystalline cellulose and sodium carboxymethylcellulose, wherein the composition has a pH of 6.0 to 7.5.

17. The topical composition of any of the preceding claims, wherein the composition has a viscosity of 100 to 400 cPs.

18. The topical composition of any of the preceding claims, wherein the pH of the composition is from 6.0 to 7.5.

19. The topical composition of any of the preceding claims for use in the treatment of allergic rhinitis or one or more symptoms thereof.

20. The topical composition of any of the preceding claims for use in the treatment of nasal congestion.

21. Use of an effective amount of the composition of any one of claims 1-18 in the manufacture of a medicament for treating allergic rhinitis or one or more symptoms thereof in a patient in need thereof, wherein the composition is to be administered nasally.

22. Use of an effective amount of the composition of any one of claims 1-18 in the manufacture of a medicament for treating nasal congestion in a patient in need thereof, wherein the composition is to be administered nasally.

23. Use of an effective amount of alcaftadine or a pharmaceutically acceptable salt thereof and a corticosteroid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating allergic rhinitis or one or more symptoms thereof in a patient in need thereof, wherein the composition is to be administered nasally.

24. The use of claim 23, wherein the alcaftadine is in free form.

25. The use of claim 23 or 24, wherein the corticosteroid is selected from alclometasone, beclometasone, betametasone, budesonide, ciclesonide, clobetasol, clobetasone, deflazacort, deprodone, dexamethasone, diflucortolone, fluocinolone, etiprednol, flunisolide, fluocinonide, fluocortolone, fluprednidene, flurometholone, fluticasone, halcinonide,

hydrocortisone, loteprednol, methylprednisolone, mometasone, prednisolone, rimexolone, triamcinolone, esters thereof, and pharmaceutically acceptable salts thereof.

26. The use of claim 23 or 24, wherein the corticosteroid is selected from beclomethasone, mometasone and esters thereof, fluticasone and esters thereof, budesonide, ciclesonide, and pharmaceutically acceptable salts thereof.

27. The use of claim 23 or 24, wherein the corticosteroid is fluticasone furoate.

28. The use of claim 23 or 24, wherein the corticosteroid is fluticasone propionate.

29. The composition of any one of claims 1-20, wherein the composition (i) has an onset of action of 15 minutes or less, (ii) exhibits a T_{max} for alcaftadine of 0.25 hours or less, or (iii) both (i) and (ii).